Evren Burakgazi Dalkilic, MD
Neurology · Camden, NJNPI 1164440483
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,311 of the $120,152 with a category attached, or 79.3%. 24 manufacturers reported payments, led by SK Life Science, Inc. at 56.7% of the total. Reporting peaked in 2024 at $43,254 and has fallen 52.5% since, to $20,537 in 2025. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $603.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$68K
- Neurelis, Inc.$49K
- Livanova USA, Inc.$2K
- AbbVie$318
- Sunovion Pharmaceuticals Inc.$176
- Neuropace, Inc.$157
- plus $551 from 18 others
Across 3 payments — averaging $3841.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$6K
- UCB, Inc.$6K
What the payments were for
- Consulting fees$4,5004%
- Speaking & faculty fees$95,31179%
- Travel & lodging$15,37813%
- Food & beverage$4,9174%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 79 | $68,075 |
| Neurelis, Inc. | 41 | $49,329 |
| Livanova USA, Inc. | 8 | $1,546 |
| AbbVie(2 entities) | 24 | $318 |
| Sunovion Pharmaceuticals Inc. | 16 | $176 |
| Neuropace, Inc. | 2 | $157 |
| UCB, Inc. | 2 | $134 |
| EMD Serono, Inc. | 6 | $86 |
| Pfizer | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Eisai Inc. | 2 | $25 |
| Lilly USA, LLC | 2 | $24 |
| Springworks Therapeutics, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| Aucta Pharmaceuticals, Inc. | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Promius Pharma LLC | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Amgen | 1 | $14 |
| Sanofi | 1 | $13 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$62,685
- VALTOCO$48,959
- Cenobamate$3,815
- VNS Therapy$1,219
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$260
- RNS Neurostimulator Kit$132
How this compares
$120,152 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 125 | $183,876 |
| XcopriCenobamate | 139 | $169,679 |
| ValtocoDiazepam | 87 | $155,622 |
| FycompaPerampanel | 60 | $76,378 |
| Lacosamide | 488 | $69,832 |
| NayzilamMidazolam | 31 | $37,218 |
| VimpatLacosamide | 21 | $34,077 |
| Levetiracetam | 791 | $26,672 |
| Lamotrigine ErLamotrigine | 49 | $25,887 |
| Clobazam | 127 | $24,984 |
| UbrelvyUbrogepant | 15 | $21,961 |
| Lamictal XrLamotrigine | 12 | $21,594 |
| Oxcarbazepine | 248 | $17,860 |
| Divalproex Sodium | 197 | $16,922 |
| Diazepam | 53 | $12,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam, Vimpat | $134 | $255,171177 claims |
| SK Life Science, Inc.Xcopri | $68,075 | $169,679139 claims |
| Neurelis, Inc.Valtoco | $49,329 | $155,62287 claims |
| Eisai Inc.Fycompa | $25 | $76,37860 claims |
| AbbVieUbrelvy | $318 | $21,96115 claims |
| PfizerDilantin | $62 | $4,18021 claims |
| Upsher-smith Laboratories LLCTopiramate | $14 | $2,470161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in Camden
- Donald BaroneCamden$235K
- Olga ThonCamden$113K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.